Peaks of Interest
Malvern Instruments Acquires Viscotek Corporation; Thermo Fisher Scientific Wins 2007 Frost and Sullivan Award; The Kinesis Group Acquires Abimed Analysen
Malvern Instruments Acquires Viscotek Corporation
Malvern Instruments (UK), a materials characterization company, announced its acquisition of Viscotek Corporation, a leading provider of chromatography solutions for the characterization of natural and synthetic polymers and proteins. Viscotek will bring new and complementary technologies and expertise to Malvern, adding gel permeation chromatography (GPC), flow injection polymer analysis (FIPA) and dilute solution viscosity (DSV), and extending the range of characterization solutions offered.
Viscotek Corporation, based in Houston, Texas, was founded in 1984 by Dr. Max Haney, inventor of the four-capillary differential viscometer detector. According to Paul Walker, Malvern's managing director, the alignment of Viscotek's products with Malvern's range will provide even more opportunity to comprehensively meet a broad range of customer needs. Viscotek's present management will continue to lead the business, which will operate as Viscotek Corporation, a Malvern Company.
Thermo Fisher Scientific Wins 2007 Frost & Sullivan Award
Thermo Fisher Scientific, Inc. (Waltham, Massachusetts) has been honored with the 2007 Frost & Sullivan Market Leadership Award for its outstanding contribution to the US High Content Screening (HCS) market. This award credits the company's expertise, insight into customer requirements, and technological innovation and advanced solutions for cell-based screening and analysis. Frost & Sullivan has identified Thermo Fisher as excellent in all areas of market leadership due to their ability to monitor market changes and implement strategies to meet the rapidly changing industry demands.
The Kinesis Group Acquires Abimed Analysen
The Kinesis group of companies (UK) announced its acquisition of Abimed Analysen, a German-based company focused on the chromatography and liquid handling markets.
According to the company, the acquisition of Abimed will provide the Kinesis group with an excellent platform to penetrate Europe's largest market.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
